2/13
09:19 am
jspr
Rating for JSPR
Medium
Report
Rating for JSPR
2/13
08:12 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $38.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $38.00 price target on the stock.
2/13
07:53 am
jspr
Jasper Therapeutics initiated with a Buy at UBS
Medium
Report
Jasper Therapeutics initiated with a Buy at UBS
1/10
10:41 am
jspr
Rating for JSPR
Medium
Report
Rating for JSPR
1/10
10:41 am
jspr
Rating for JSPR
Medium
Report
Rating for JSPR
1/9
10:24 am
jspr
Rating for JSPR
Report
Rating for JSPR
1/9
10:24 am
jspr
Rating for JSPR
Report
Rating for JSPR
1/6
08:44 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
1/6
08:44 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
1/6
08:27 am
jspr
Rating for JSPR
Medium
Report
Rating for JSPR
1/6
08:27 am
jspr
Rating for JSPR
Medium
Report
Rating for JSPR
12/23
08:57 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
12/23
08:57 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
12/23
08:52 am
jspr
Rating for JSPR
Low
Report
Rating for JSPR
12/23
08:52 am
jspr
Rating for JSPR
Low
Report
Rating for JSPR
12/6
08:06 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
12/6
05:49 am
jspr
Rating for JSPR
Medium
Report
Rating for JSPR
12/6
05:49 am
jspr
Rating for JSPR
Medium
Report
Rating for JSPR
12/5
04:08 pm
jspr
Jasper Therapeutics initiated with an Outperform at BMO Capital
Medium
Report
Jasper Therapeutics initiated with an Outperform at BMO Capital
12/5
04:08 pm
jspr
Jasper Therapeutics initiated with an Outperform at BMO Capital
Medium
Report
Jasper Therapeutics initiated with an Outperform at BMO Capital